MF Researcher Database

Researcher Database

Advance

Yamaoka Toshimitsu

■FacultyAdvanced Cancer Translational Research Institute
■PositionAssociate Professor
Last Updated :2025/10/23

Researcher

基本情報

Profile and Settings

  • 氏名

    Yamaoka Toshimitsu

Affiliation

  • Advanced Cancer Translational Research Institute, Associate Professor

Location

  • Hatanodai Campus

Degree

  • Doctor of Medical Science, Showa University, Mar. 2004

Social Contributions

  • MDPI, Biomolecules, Paper, Chief, Molecular Pathology, Diagnostics and Therapeutics of Lung Disease, 30 Jun. 2025, 30 Jun. 2026

Achievements

Published Papers

  • 肺腺癌細胞PC-9における第3世代EGFR-TKI、オシメルチニブの獲得耐性機序の検討, 山岡 利光; 岸野 康成; 楠本 壮二郎; 安藤 浩一; 大森 亨; 相良 博典; 鶴谷 純司, 日本癌学会総会記事, 80回:[P16 - 4], Sep. 2021
  • Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis, ANDO Koichi;MANABE Ryo;KISHINO Yasunari;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;OHMORI Tohru;SAGARA Hironori, Cancers (Basel), 13(15):3704, Jul. 2021, Peer-reviewed
  • Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis., ANDO Koichi;MANABE Ryo;KISHINO Yasunari;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori, Curr Oncol, 28(2):1094 - 1113, Feb. 2021, Peer-reviewed
  • Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells., MATSUNAGA Yuki;YAMAOKA Toshimitsu;OHBA Motoi;MIURA Sakiko;MASUDA Hiroko;SANGAI Takafumi;TAKIMOTO Masafumi;NAKAMURA Seigo;TSURUTANI Junji, Antibodies (Basel), 10(1):6, Feb. 2021, Peer-reviewed
  • Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury., OHMORI Tohru;YAMAOKA Toshimitsu;ANDO Koichi;KUSUMOTO Sojiro;KISHINO Yasunari;MANABE Ryo;SAGARA Hironori, Int J Mol Sci, 22(2):792, Jan. 2021, Peer-reviewed
  • HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer., YAMAOKA Toshimitsu;TSURUTANI Junji;SAGARA Hironori;OHMORI Tohru, Transl Lung Cancer Res, 9(5):2178 - 2183, Oct. 2020
  • Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis., ANDO Koichi;KISHINO Yasunari;HOMMA Tetsuya;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori, Cancers (Basel), 12(7):1905, Jul. 2020, Peer-reviewed
  • Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis., ANDO Koichi;AKIMOTO Kaho;SATO Hiroki;MANABE Ryo;KISHINO Yasunari;HOMMA Tetsuya;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;OHMORI Tohru;SAGARA Hironori, Cancers (Basel), 12(4):942, Apr. 2020, Peer-reviewed
  • Inhibition of Virus-Induced Cytokine Production from Airway Epithelial Cells by the Late Addition of Budesonide., HOMMA Tetsuya;FUKUDA Yosuke;UCHIDA Yoshitaka;UNO Tomoki;JINNO Megumi;KISHINO Yasunari;YAMAMOTO Mayumi;SATO Hiroki;AKIMOTO Kaho;KANEKO Keisuke;FUJIWARA Akiko;SATO Haruna;HIRAI Kuniaki;MIYATA Yoshito;INOUE Hideki;OHTA Shin;WATANABE Yoshio;KUSUMOTO Sojiro;ANDO Koichi;SUZUKI Shintaro;YAMAOKA Toshimitsu;TANAKA Akihiko;OHMORI Tohru;SAGARA Hironori, Medicina (Kaunas), 56(3):98, Feb. 2020, Peer-reviewed
  • Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury., YAMAOKA Toshimitsu;ARATA Satoru;HOMMA Mayumi;HOMMA Tetsuya;KUSUMOTO Sojiro;ANDO Koichi;MANABE Ryo;KISHINO Yasunari;OHBA Motoi;TSURUTANI Junji;TAKIMOTO Masafumi;OHMORI Tohru;SAGARA Hironori, Int J Mol Sci, 20(16):E4021, Aug. 2019, Peer-reviewed
  • Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib., YAMAOKA Toshimitsu;OHBA Motoi;MATSUNAGA Yuki;TSURUTANI Junji;OHMORI Tohru, J Vis Exp, (148):e, Jun. 2019, Peer-reviewed
  • Elucidation of carcinogenesis mechanism in chronic obstructive pulmonary disease (COPD) combined lung cancer., YAMAOKA Toshimitsu, Impact, 2019(6):23 - 25, Jun. 2019
  • KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR., NAKATANI Kaori;YAMAOKA Toshimitsu;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;KUSUMOTO Sojiro;TAKI (TAKEMOTO) Iori;KAMEI Daisuke;IWAI Shinichi;TSURUTANI Junji;OHMORI Tohru, Mol Cancer Ther, 18(1):112 - 126, Jan. 2019, Peer-reviewed
  • Receptor Tyrosine Kinase-Targeted Cancer Therapy., YAMAOKA Toshimitsu;KUSUMOTO Sojiro;ANDO Koichi;OHBA Motoi;OHMORI Tohru, Int J Mol Sci, 19(11):E3491, Nov. 2018, Peer-reviewed
  • Receptor Tyrosine Kinase-Targeted Cancer Therapy., Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T, International journal of molecular sciences, 19(11), Nov. 2018
  • Receptor Tyrosine Kinase-Targeted Cancer Therapy., Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T, International journal of molecular sciences, 19(11), Nov. 2018
  • Receptor Tyrosine Kinase-Targeted Cancer Therapy., Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T, International journal of molecular sciences, 19(11), Nov. 2018
  • KRAS and EGFR amplifications mediate resistance to rociletinib and osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR., Nakatani K; Yamaoka T; Ohba M; Fujita KI; Arata S; Kusumoto S; Taki-Takemoto I; Kamei D; Iwai S; Tsurutani J; Ohmori T, Molecular cancer therapeutics, 18(1):112 - 126, Oct. 2018
  • KRAS and EGFR amplifications mediate resistance to rociletinib and osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR., Nakatani K; Yamaoka T; Ohba M; Fujita KI; Arata S; Kusumoto S; Taki-Takemoto I; Kamei D; Iwai S; Tsurutani J; Ohmori T, Molecular cancer therapeutics, 18(1):112 - 126, Oct. 2018
  • KRAS and EGFR amplifications mediate resistance to rociletinib and osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR., Nakatani K; Yamaoka T; Ohba M; Fujita KI; Arata S; Kusumoto S; Taki-Takemoto I; Kamei D; Iwai S; Tsurutani J; Ohmori T, Molecular cancer therapeutics, 18(1):112 - 126, Oct. 2018
  • Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis, MANABE Ryo;ANDO Koichi;KUSUMOTO Sojiro;TANAKA Akihiko;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori, Showa Univ J Med Sci, 30(2):309 - 315, Jun. 2018, Peer-reviewed
  • Efficacy and Safety of Long-acting Beta-2 Agonist and Long-acting Muscarinic Antagonist Combinations in Patients with Chronic Obstructive Pulmonary Disease: Meta-analysis of Phase 3 Randomized Trials, ANDO Koichi;TANAKA Akihiko;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci, 30(2):159 - 174, Jun. 2018, Peer-reviewed, DOI:10.15369/sujms.30.159
  • Comparative Efficacy and Safety of Anti-Interleukin-5 Therapies and Placebo in Patients with Uncontrolled Eosinophilic Asthma:A Systematic Review and Meta-analysis of Phase 3 Trials, ANDO Koichi;TANAKA Akihiko;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;OHMORI Tohru;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci, 30(1):11 - 25, Mar. 2018, Peer-reviewed, DOI:10.15369/sujms.30.11
  • A Long-acting Muscarinic Antagonist （LAMA） Added to an Inhaled Corticosteroid and Long-acting Beta-2 Agonist Versus LAMA Alone in Moderate-to-severe Chronic Obstructive Pulmonary Disease:A Systematic Review and Meta-analysis of Randomized Trials, ANDO Koichi;TANAKA Akihiko;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci, 30(1):1 - 9, Mar. 2018, Peer-reviewed, DOI:10.15369/sujms.30.1
  • EGFR-TKI Versus Chemotherapy for Previously Untreated Advanced Non-Small Cell Lung Cancer in Asians: A Meta-Analysis, ANDO Koichi;KUSUMOTO Sojiro;TANAKA Akihiko;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci, 29(4):435 - 443, Dec. 2017, Peer-reviewed, DOI:10.15369/sujms.29.435
  • Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms, YAMAOKA Toshimitsu;OHBA Motoi;OHMORI Tohru, Int J Mol Sci, 18(11):2420, Nov. 2017, Peer-reviewed
  • A Comparison of Adverse Effect Profiles of Two Anti-IL-5 Therapies in Adults with Uncontrolled Asthma―A Network Meta-analysis of Phase 3 Trials―, ANDO Koichi;MIYATA Yoshito;HIRAI Kuniaki ;MIZUMA Hiroko ;YAMAGUCHI Munehiro;MURATA Yasunori;HOMMA Tetsuya;OHTA Shin;YAMAMOTO Mayumi;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;YOKOE Takuya;OHNISHI Tsukasa;OHMORI Tohru;INOUE Shin;SAGARA Hironori, Showa Univ J Med Sci, 29(3):279 - 287, Sep. 2017, Peer-reviewed
  • Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure., YAMAOKA Toshimitsu;OHBA Motoi;ARATA Satoru;OHMORI Tohru, J Vis Exp, (126):e, Aug. 2017, Peer-reviewed
  • Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;ARATA Satoru;MURATA Yasunori;KUSUMOTO Sojiro;ANDO Koichi;ISHIDA Hiroo;OHNISHI Tsukasa;SASAKI Yasutsuna, Mol Cancer Res, 15(7):915 - 928, Jul. 2017, Peer-reviewed
  • Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation, Toshimitsu Yamaoka; Tohru Ohmori; Motoi Ohba; Satoru Arata; Yasunori Murata; Sojiro Kusumoto; Koichi Ando; Hiroo Ishida; Tsukasa Ohnishi; Yasutsuna Sasaki, MOLECULAR CANCER RESEARCH, 15(7):915 - 928, Jul. 2017
  • Comparing the Adverse Event Profiles of Nivolumab and Docetaxel in Previously-treated or Refractory Advanced Non-small Cell Lung Cancer: A Meta-analysis of Two Phase 3 Trials, ANDO Koichi;MURATA Yasunori;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;YOKOE Takuya;OKUDA Kentaro ;OHNISHI Tsukasa;INOUE Shin;OHMORI Tohru;SAGARA Hironori, Showa Univ J Med Sci, 29(1):69 - 77, Mar. 2017, Peer-reviewed, DOI:10.15369/sujms.29.69
  • Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation., YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;ARATA Satoru;KISHINO Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;HIROSE Takashi;OHNISHI Tsukasa;SASAKI Yasutsuna, Mol Cancer Ther, 15(12):3040 - 3054, Dec. 2016, Peer-reviewed
  • Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation, Toshimitsu Yamaoka; Tohru Ohmori; Motoi Ohba; Satoru Arata; Yasunari Kishino; Yasunori Murata; Sojiro Kusumoto; Hiroo Ishida; Takao Shirai; Takashi Hirose; Tsukasa Ohnishi; Yasutsuna Sasaki, MOLECULAR CANCER THERAPEUTICS, 15(12):3040 - 3054, Dec. 2016
  • Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer, HIROSE Takashi;FUJITA Ken-ichi;KUSUMOTO Sojiro;OKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OKUDA Kentaro;OHMORI Tohru;SASAKI Yasutsuna, Lung Cancer, 93:69 - 76, Mar. 2016, Peer-reviewed
  • Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer, Takashi Hirose; Ken-ichi Fujita; Sojiro Kusumoto; Yasunari Oki; Yasunori Murata; Tomohide Sugiyama; Hiroo Ishida; Takao Shirai; Masanao Nakashima; Toshimitsu Yamaoka; Kentaro Okuda; Tohru Ohmori; Yasutsuna Sasaki, LUNG CANCER, 93:69 - 76, Mar. 2016
  • Up-regulation of Syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells, Yoko Toba Ichihashi; Toshimitsu Yamaoka; Tohru Ohmori; Motoi Ohba, Biochemistry and Biophysics Reports, 5:1 - 7, Mar. 2016
  • Up-regulation of Syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells, TOBA-ICHIHASHI Yoko;YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi, Biochem Biophys Rep, 5:1 - 7, Nov. 2015, Peer-reviewed
  • Up-regulation of Syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells., TOBA-ICHIHASHI Yoko;YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi, Biochem Biophys Rep, 5:1 - 7, Nov. 2015, Peer-reviewed
  • Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer., ISHIDA Koko;HIROSE Takashi;YOKOUCHI Junichi ;OKI Yasunari;KUSUMOTO Sojiro;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OHNISHI Tsukasa;OHMORI Tohru;KAGAMI Yoshikazu, Mol Clin Oncol, 2(3):405 - 410, May 2014, Peer-reviewed
  • Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease., OKUDA Kentaro;HIROSE Takashi;OKI Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OHNISHI Tsukasa;OHMORI Tohru, Anticancer Res, 32(12):5475 - 5480, Dec. 2012, Peer-reviewed
  • 進行再発非小細胞肺癌に対するセカンドライン化学療法の検討, 白井　崇生;廣瀬　敬;村田　泰規;大木　康成;楠本　壮二郎;杉山　智英;石田　博雄;中嶌　賢尚;大西　司;山岡　利光;大森　亨;奥田　健太郎, 昭和医学会雑誌, 72(4):446 - 452, Aug. 2012, Peer-reviewed, DOI:10.14930/jsma.72.446
  • Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer., HIROSE Takashi;MURATA Yasunori;OKI Yasunari;SUGIYAMA Tomohide;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masano;山岡　利光;OKUDA Kentaro;OHNISHI Tsukasa;OHMORI Tohru, Oncol Res, 20(2月3日):131 - 137, Feb. 2012, Peer-reviewed
  • The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant non-small cell lung cancer, Toshimitsu Yamaoka; Tohru Ohmori, Japanese Journal of Cancer and Chemotherapy, 39(6):857 - 862, 2012
  • Myelosuppression induced by concurrent chemoradiotherapy as a prognostic factor for patients with locally advanced non-small cell lung cancer, Yukiko Kishida; Takashi Hirose; Takao Shirai; Tomohide Sugiyama; Soujiro Kusumoto; Toshimitsu Yamaoka; Kentaro Okuda; Mitsuru Adachi; Akihiro Nakamura, ONCOLOGY LETTERS, 2(5):949 - 955, Sep. 2011
  • Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer, Takashi Hirose; Masanao Nakashima; Takao Shirai; Sojiro Kusumoto; Tomohide Sugiyama; Toshimitsu Yamaoka; Kentaro Okuda; Tsukasa Ohnishi; Tohru Ohmori; Mitsuru Adachi, LUNG CANCER, 73(3):345 - 350, Sep. 2011
  • Specific epidermal growth factor receptor autophosphorylation sites promote mouse colon epithelial cell chemotaxis and restitution, Toshimitsu Yamaoka; Mark R. Frey; Rebecca S. Dise; Jessica K. Bernard; D. Brent Polk, AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 301(2):G368 - G376, Aug. 2011
  • Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer, Yasunori Murata; Takashi Hirose; Toshimitsu Yamaoka; Takao Shirai; Kentaro Okuda; Tomohide Sugiyama; Sojiro Kusumoto; Masanao Nakashima; Tohru Ohmori; Mitsuru Adachi, EUROPEAN JOURNAL OF CANCER, 47(9):1336 - 1342, Jun. 2011
  • [A case of pulmonary aspergilloma concomitant with allergic bronchopulmonary aspergillosis]., Kusumoto S; Tanaka A; Ohta S; Sugiyama T; Shirai T; Yamaoka T; Okuda K; Hirose T; Ohnishi T; Adachi M, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 49(5):377 - 382, May 2011
  • Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer, Yasunari Oki; Takashi Hirose; Toshimitsu Yamaoka; Sojiro Kusumoto; Takao Shirai; Tomohide Sugiyama; Kentaro Okuda; Masanao Nakashima; Yasunori Murata; Tohru Ohmori; Mitsuru Adachi, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 67(4):791 - 797, Apr. 2011
  • Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?, Takashi Hirose; Kentaro Okuda; Toshimitsu Yamaoka; Koko Ishida; Sojiro Kusumoto; Tomohide Sugiyama; Takao Shirai; Tsukasa Ohnshi; Tohru Ohmori; Mitsuru Adachi, LUNG CANCER, 71(2):224 - 228, Feb. 2011
  • IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF-alpha and IL-1 beta, Masayuki Iyoda; Takanori Shibata; Mio Kawaguchi; Nobuyuki Hizawa; Toshimitsu Yamaoka; Fumio Kokubu; Tadao Akizawa, AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 298(3):F779 - F787, Mar. 2010
  • Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer, Sojiro Kusumoto; Takashi Hirose; Motoko Fukayama; Daisuke Kataoka; Kenji Hamada; Tomohide Sugiyama; Takao Shirai; Toshimitsu Yamaoka; Kentaro Okuda; Tsukasa Ohnishi; Tohru Ohmori; Mitsutaka Kadokura; Mitsuru Adachi, ONCOLOGY REPORTS, 22(5):1157 - 1162, Nov. 2009
  • Combination Effect between Bortezomib and Tumor Necrosis Factor alpha on Gefitinib-resistant Non-small Cell Lung Cancer Cell Lines, Sojiro Kusumoto; Tomohide Sugiyama; Koichi Ando; Takamichi Hosaka; Hiroo Ishida; Takao Shirai; Toshimitsu Yamaoka; Kentaro Okuda; Takashi Hirose; Tsukasa Ohnishi; Fumiko Inoue; Tomoko Kanome; Tsuyoki Kadofuku; Nagahiro Saijo; Mitsuru Adachii; Tohru Ohmori, ANTICANCER RESEARCH, 29(6):2315 - 2322, Jun. 2009
  • Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer, Takashi Hirose; Tomohide Sugiyama; Sojiro Kusumoto; Takao Shirai; Masanao Nakashima; Toshimitsu Yamaoka; Kentaro Okuda; Keiichi Ogura; Tsukasa Ohnishi; Tohru Ohmori; Mitsuru Adachi, ANTICANCER RESEARCH, 29(5):1733 - 1738, May 2009
  • Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis, Masayuki Iyoda; Takanori Shibata; Mio Kawaguchi; Toshimitsu Yamaoka; Tadao Akizawa, KIDNEY INTERNATIONAL, 75(10):1060 - 1070, May 2009
  • Patient willingness to undergo chemotherapy and thoracic radiotherapy for locally advanced non-small cell lung cancer, Takashi Hirose; Toshimitsu Yamaoka; Tsukasa Ohnishi; Tomohide Sugiyama; Sojiro Kusumoto; Takao Shirai; Kentaro Okuda; Tohru Ohmori; Mitsuru Adahi, PSYCHO-ONCOLOGY, 18(5):483 - 489, May 2009
  • The UGT1A1*28 Genotype and the Toxicity of Low-Dose Irinotecan in Patients With Advanced Lung Cancer, Tomohide Sugiyama; Takashi Hirose; Sojiro Kusumoto; Takao Shirai; Toshimitsu Yamaoka; Kentaro Okuda; Tsukasa Ohnishi; Tohru Ohmori; Mitsuru Adachi, ONCOLOGY RESEARCH, 18(7):337 - 342, 2009
  • Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer, Chiho Yashiki; Takashi Hirose; Kentaro Okuda; Toshimitsu Yamaoka; Tsukasa Ohnishi; Mitsuru Adachi; Akihiro Nakamura, Japanese Journal of Cancer and Chemotherapy, 36(11):1839 - 1843, 2009
  • Drug Accumulation and Efflux Do not Contribute to Acquired Gefitinib Resistance, Sojiro Kusumoto; Tomohide Sugiyama; Masanao Nakashima; Toshimitsu Yamaoka; Takashi Hirose; Tsukasa Ohnishi; Naoya Horichi; Mitsuru Adachi; Kazuto Nishio; Nagahiro Saijo; Toshio Kuroki; Tohru Ohmori, NEW TRENDS IN THE MOLECULAR AND BIOLOGICAL BASIS FOR CLINICAL ONCOLOGY, :127 - +, 2009
  • Epidermal Growth Factor (EGF) Receptor Kinase Activity is Required for Tumor Necrosis Factor (TNF)-alpha Mediated Intestinal Epithelial Survival, Toshimitsu Yamaoka; D. Brent Polk; Tohru Ohmori; Sojiro Kusumoto; Tomohide Sugiyama; Takao Shirai; Masanao Nakashima; Kentaro Okuda; Takashi Hirose; Tsukasa Ohnishi; Naoya Horichi; Mitsuru Adachi, NEW TRENDS IN THE MOLECULAR AND BIOLOGICAL BASIS FOR CLINICAL ONCOLOGY, :37 - +, 2009
  • Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis, Toshimitsu Yamaoka; Fang Yan; Hanwei Cao; Stuart S. Hobbs; Rebecca S. Dise; Wei Tong; D. Brent Polk, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 105(33):11772 - 11777, Aug. 2008
  • Patient satisfaction with sedation for flexible bronchoscopy, Takashi Hirose; Kentaro Okuda; Hiroo Ishida; Tomohide Sugiyama; Sojiro Kusumoto; Masanao Nakashima; Toshimitsu Yamaoka; Mitsuru Adachi, RESPIROLOGY, 13(5):722 - 727, Jul. 2008
  • [Two cases with recurrent non-small cell lung cancer successfully treated with cisplatin and S-1]., Hirose T; Hosaka T; Nakashima M; Sugiyama T; Ishida H; Yamaoka T; Okuda K; Adachi M, Gan to kagaku ryoho. Cancer & chemotherapy, 35(2):327 - 330, Feb. 2008
  • Effectiveness of intensive follow-up after response in patients with small cell lung cancer, Tomohide Sugiyama; Takashi Hirose; Takamichi Hosaka; Sojiro Kusumoto; Masanao Nakashima; Toshimitsu Yamaoka; Kentaro Okuda; Tohru Ohmori; Mitsuru Adachi, LUNG CANCER, 59(2):255 - 261, Feb. 2008
  • [Two cases of successfully treated invasive pulmonary aspergillosis following influenza virus infection]., Ohnishi T; Andou K; Kusumoto S; Sugiyama H; Hosaka T; Ishida H; Shirai K; Nakashima M; Yamaoka T; Okuda K; Hirose T; Horichi N; Adachi M, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 45(4):349 - 355, Apr. 2007
  • Comparison of Biweekly and Triweekly Therapy with Docetaxel and Irinotecan for Refractory or Relapsed Advanced Non-small-cell Lung cancer, ISHIDA Hiroo; HIROSE Takashi; SHIRAI Takao; OKUDA Kentaro; SUGIYAMA Tomohide; KUSUMOTO Sojiro; HOSAKA Takamichi; ANDO Kohichi; NAKASHIMA Masanao; YAMAOKA Toshimitsu; OHNISHI Tsukasa; HORICHI Naoya; OHMORI Tohru; ADACHI Mitsuru, Showa Univ J Med Sci, 19(2):103 - 111, 2007
  • Regulation of apoptosis during homeostasis and disease in the intestinal epithelium, KL Edelblum; F Yan; T Yamaoka; DB Polk, INFLAMMATORY BOWEL DISEASES, 12(5):413 - 424, May 2006
  • Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer, T Hirose; N Horichi; T Ohmori; T Shirai; S Sohma; T Yamaoka; T Ohnishi; M Adachi, LUNG CANCER, 39(1):91 - 97, Jan. 2003

Presentations

  • Attenuation of SLC46A3 through methylation confers resistance to T-DM1 in gastric cancer N87 cells, 山岡利光　石川文博　長谷部友紀　松尾理加　伊藤寛晃　鶴谷純司, 第84回日本癌学会学術総会, 25 Sep. 2025, 日本癌学会, 金沢
  • メチル化によるSLC46A3発現低下が胃がん細胞N87のT- DM1感受性に与える影響, 山岡利光　鶴谷純司, 第29回日本がん分子標的治療学会学術集会, 03 Jul. 2025, 日本がん分子標的治療学会, 札幌
  • Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for ES-SCLC, 安藤　浩一;岸野　康成;楠本　壮二郎;山岡　利光;田中　明彦;大森　亨;相良　博典, 第62回日本肺癌学会学術集会, 27 Nov. 2021, 横浜およびWEB配信
  • EGFR遺伝子変異を有する肺腺癌細胞PC-9における第３世代EGFR-TKI, オシメルチニブの獲得耐性機序の検討, 山岡　利光;岸野　康成;楠本　壮二郎;安藤　浩一;大森　亨;相良　博典;鶴谷　純司, 第62回日本肺癌学会学術集会, 27 Nov. 2021, 横浜・LIVE配信・オンデマンド配信
  • Mechanism of resistance to third-generation EGFR-TKI, osimertinib, in lung adenocarcinoma PC-9 cells, 山岡　利光;岸野　康成;楠本　壮二郎;安藤　浩一;大森　亨;相良　博典;鶴谷　純司, 第80回⽇本癌学会学術総会, 02 Oct. 2021, 横浜
  • EGFRチロシンキナーゼ阻害剤によるSPC-TNFトランスジェニックマウスにおける肺組織損傷とアポトーシス誘導機序の検討, 山岡　利光;大森　亨;安藤　浩一;楠本　壮二郎;本間　哲也;岸野　康成;眞鍋　亮;相良　博典;鶴谷　純司, 第60回日本呼吸器学会学術講演会, 20 Sep. 2020, Web開催
  • 高齢者非小細胞肺癌に対するImmune checkpoint inhibitorの有効性に関するメタ解析, 安藤　浩一;眞鍋　亮;岸野　康成;楠本　壮二郎;山岡　利光;大森　亨;相良　博典, 第60回日本肺癌学会学術集会, 08 Dec. 2019, 大阪
  • KRAS Amplification Mediates Resistance to Osimertinib in Acquired Afatinib-Resistant PC-9 cells Harboring Exon 19 Deletion/T790M in EGFR, 山岡　利光;大森　亨;相良　博典;鶴谷　純司, 第23回日本がん分子標的治療学会学術集会, 13 Jun. 2019, 大阪
  • EGFR遺伝子変異陽性(exon19del/T790M)肺腺癌細胞株におけるオシメルチニブ獲得耐性機序., 山岡　利光, 第59回日本呼吸器学会学術講演会, 12 Apr. 2019, 東京
  • KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR., YAMAOKA Toshimitsu;OHBA Motoi;KISHINO Yasunari;KUSUMOTO Sojiro;TSURUTANI Junji;OHMORI Tohru, AACR Annual Meeting 2019, 01 Apr. 2019, Atlanta
  • T790M-EGFRによりアファチニブ耐性をきたした肺腺癌細胞株におけるロシレチニブ耐性機序の検討, 山岡　利光;楠本　壮二郎;安藤　浩一;石田　博雄;大西　司;相良　博典;大森　亨, 第59回日本肺癌学会学術集会, 30 Nov. 2018, 東京
  • Evolution of kinase inhibitors sensitivity in three-dimensional suspended spheroid culture platform, ITO Risa;SUZUKI Toshihiro;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;OGASAWARA Yuki, 第77回日本癌学会学術総会, 28 Sep. 2018, 大阪
  • Mechanism of resistance to third-generation EGFR-TKI, rociletinib, in lung adenocarcinoma cells with EGFR-T790M mutation, YAMAOKA Toshimitsu;NAKATANI Kaori;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;IWAI Shinichi;OHMORI Tohru, 第77回日本癌学会学術総会, 28 Sep. 2018, 大阪
  • 10-methyl-aplog-1 enhances the cytotoxic effects of HDAC inhibitor in esophageal squamous carcinoma cells, OHBA Motoi;TOYA Etsuko;ARATA Satoru;YAMAOKA Toshimitsu;IRIE Kazuhiro;SASAKI Yasutsuna, 第16回日本臨床腫瘍学会学術集会, 21 Jul. 2018, 神戸
  • Resistance mechanisms to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in lung adenocarcinoma cells harboring the EGFR-T790M mutation, NAKATANI Kaori;YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;FUJITA Ken-ichi;TAKI Iori;KAMEI Daisuke;IWAI Shinichi;SASAKI Yasutsuna, 18th World Congress of Basic and Clinical Pharmacology (WCP2018), 05 Jul. 2018, Kyoto
  • Resistance mechanisms to third-generation EGFR TKIs in lung adenocarcinoma harboring EGFR T790M mutation, 中谷　香織;山岡　利光;大森　亨;大場　基;藤田　健一;滝　伊織;亀井　大輔;岩井　信市, 日本薬学会第138年会, 28 Mar. 2018, 金沢
  • 10-methyl-aplog-1 augments the therapeutic efficacy of HDAC inhibitor in esophageal squamous carcinoma cells, 大場　基;外谷　衣都子;荒田　悟;山岡　利光;入江　一浩;佐々木　康綱, 第76回日本癌学会学術総会, 28 Sep. 2017, 横浜
  • Dual resistance of EGFR-mutant lung adenocarcinoma cells to EGFR and MET inhibitors, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;ARATA Satoru;MURATA Yasunori;KISHINO Yasunari;KUSUMOTO Sojiro;ISHIDA Hiroo;OHNISHI Tsukasa;SASAKI Yasutsuna, 第75回日本癌学会学術総会, 08 Oct. 2016, 横浜
  • Combination effect of afatinib and BI836845, a humanized IGF ligand-neutralizing antibody, on EGFR-TKI-resistant NSCLC, OHMORI Tohru;YAMAOKA Toshimitsu;ARATA Satoru;OHBA Motoi;MURATA Yasunori;KISHINO Yasunari;KUSUMOTO Sojiro;HIROSE Takashi;ONISHI Tsukasa;NISHIO Kazuto, 第75回日本癌学会学術総会, 07 Oct. 2016
  • Mechanism underlying acquisition of dual resistance to EGFR and MET inhibitors by EGFR-mutant lung adenocarcinoma cells, 山岡　利光, 第14回日本臨床腫瘍学会学術集会, 28 Jul. 2016, 神戸
  • Mechanism underlying acquisition of dual resistance to EGFR and MET inhibitors by EGFR-mutant lung adenocarcinoma cells, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;MURATA Yasunori;KISHINO Yasunari;KUSUMOTO Sojiro;ISHIDA Hiroo;OHNISHI Tsukasa;SASAKI Yasutsuna, American Association for Cancer Research Annual Meeting 2016, 18 Apr. 2016, New Orleans
  • The effect of kinase signaling for miR-205 regulation in gefitinib-resistant lung cancer cell lines, SUZUKI Toshihiro;NAGASAWA Ikuko;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;KOYAMA Kiyotaka;OGASAWARA Yuki, AACR Annual Meeting 2016, 18 Apr. 2016, New Orleans
  • Combination effect of afatinib and BI 836845, a humanized IGF ligand-neutralizing antibody, on EGFR-TKI-resistant NSCLC cells, OHMORI Tohru;YAMAOKA Toshimitsu;ARATA Satoru;OHBA Motoi;MURATA Yasunori;KISHIDA Yasunari;KUSUMOTO Sojiro;NAKASHIMA Masanao;HIROSE Takashi;OHNISHI Tsukasa;NISHIO Kazuto, American Association for Cancer Research Annual Meeting 2016, 18 Apr. 2016, New Orleans
  • Mechanism underlying acquisition of dual resistance to EGFR & MET inhibitors by EGFR-mutant lung adenocarcinoma cells, YAMAOKA Toshimitsu;OHMORI Tohru;OHBA Motoi;TOYA Etsuko;KISHINO Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;OHNISHI Tsukasa;SAGARA Hironori;SASAKI Yasutsuna, 第74回日本癌学会学術総会, 09 Oct. 2015, 名古屋
  • Mechanism underlying acquisition of dual resistance to EGFR & MET inhibitors by EGFR-mutant lung adenocarcinoma cells, 山岡　利光;大森　亨;大場　基;外谷　衣都子;岸野　康成;村田　泰規;楠本　壮二郎;石田　博雄;大西　司;相良　博典;佐々木　康綱, 第74回日本癌学会学術総会, 09 Oct. 2015, 名古屋
  • The effect of ErbB3 phosphorylation for miR-205 regulation in gefitinib-resistant lung cancer cell lines, SUZUKI Toshihiro;NAGASAWA Ikuko;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;KOYAMA Kiyotaka;OGASAWARA Yuki, 第74回日本癌学会学術総会, 08 Oct. 2015, 名古屋
  • Inhibition of metastasis of lung adenocarcinoma cells via the perturbed localization of Rab11FIP1 by PKCeta depletion, OHBA Motoi;TOYA Etsuko;YAMAOKA Toshimitsu;SASAKI Yasutsuna, 第13回日本臨床腫瘍学会集会, 17 Jul. 2015, 札幌
  • Association of pharmacokinetics or pharmacogenomics with toxicity of erlotinib in patients with recurrent advanced non-small cell lung cancer., HIROSE Takashi;FUJITA Ken-ichi;KUSUMOTO Sojiro;OKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OKUDA Kentaro;OHNISHI Tsukasa;OHMORI Tohru;SASAKI Yasutsuna;TAMURA Atsuhisa;OHTA Ken, The 39th European Society for Medical Oncology annual meeting, 27 Sep. 2014, Madrid
  • The effect of kinase signaling for miR-205 regulation in gefitinib-resistant lung cancer cell lines, SUZUKI Toshihiro;NAGASAWA Ikuko;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;KOYAMA Kiyoataka;OGASAWARA Yuki, 第73回日本癌学会学術総会, 27 Sep. 2014, 横浜
  • EGFR transactivation by TNF protects EGFR-TKI, gefitinib induced pulmonary injury in SP-C/TNF transgenic mice, YAMAOKA Toshimitsu;OHMORI Tohru;OHKI Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;HIROSE Takashi;OHNISHI Tsukasa;SASAKI Yasutsuna, 第73回日本癌学会学術総会, 26 Sep. 2014, 横浜
  • PKCη controls the proliferation of lung adenocarcinoma cells via EGFR and MET endocytic trafficking., OHBA Motoi;TOYA Etsuko;YAMAOKA Toshimitsu;OHMORI Tohru;SASAKI Yasutsuna, 第73回日本癌学会学術総会, 25 Sep. 2014, 横浜
  • Involvement of protein kinase C eta in the migration and invasion of human lung adenocarcinoma cells, 外谷　衣都子;大場　基;山岡　利光;大森　亨;佐々木　康綱, 第12回日本臨床腫瘍学会学術集会, 18 Jul. 2014, 福岡
  • PKCη controls the proliferation of lung adenocarcinoma cells via EGFR and MET endocytic trafficking, OHBA Motoi;TOYA Etsuko;YAMAOKA Toshimitsu;OHMORI Tohru;KUROKI Toshio;SASAKI Yasutsuna, 第12回日本臨床腫瘍学会学術集会, 18 Jul. 2014, 福岡
  • Tivantinib, shows a synergistic growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein, OHMORI Tohru;YAMAOKA Toshimitsu;TOYA Etsuko;OHBA Motoi;KOIZUMI Fumiaki;NISHIO Kazuto;AKINAGA Shiro, 第12回日本臨床腫瘍学会学術集会, 17 Jul. 2014, 福岡
  • TNF transactivation of EGFR protects EGFR-TKI induced pulmonary injury in SPC-TNF transgenic mice, 山岡　利光;外谷　衣都子;大場　基;大木　康成;村田　泰規;楠本　壮二郎;石田　博雄;大森　亨;佐々木　康綱, 第12回日本臨床腫瘍学会学術集会, 17 Jul. 2014, 福岡
  • 非小細胞肺癌におけるエルロチニブとゾレドロン酸併用療法の有用性に関する後方視的解析, 大木　康成;廣瀬　敬;白井　崇生;村田　泰規;杉山　智英　　;楠本　壮二郎;石田　博雄;中嶌　賢尚;山岡　利光;奥田　健太郎;大西　司;大森　亨;相良　博典, 第54回日本呼吸器学会学術講演会, 26 Apr. 2014, 大阪
  • Pharmacokinetics, pharmacogenetics and toxicity of erlotinib in patients with non-small cell lung cancer, 廣瀬　敬;藤田　健一;楠本　壮二郎;白井　崇生;村田　泰則;大木　康成;杉山 　智英;石田　博雄;中嶌　賢尚;山岡　利光;奥田　健太郎;大西　司;大森　亨;佐々木　康綱;田村　厚久;大田　健, 第54回日本呼吸器学会学術講演会, 26 Apr. 2014, 大阪
  • 小細胞肺癌患者における末梢血がん細胞数と予後の検討, 白井　崇生;廣瀬　敬;大木　康成;村田　泰規;楠本　壮二郎;杉山　智英;石田　博雄;中鴬　賢尚;山岡　利光;奥田　健太郎;大西　司;大森　亨;相良　博典, 第54回日本呼吸器学会学術講演会, 25 Apr. 2014, 大阪
  • TNF transactivation of EGFR protects EGFR-TKI, gefitinib induced pulmonary epithelial cell apoptosis and injury in TNF transgenic mice., YAMAOKA Toshimitsu;OKI Yasunari;MURATA Yasunori;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;TOYA Etsuko;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori;SASAKI Yasutsuna, 105th American Association for Cancer Research annual meeting, 07 Apr. 2014, San Diego
  • Comtribution of miR-205 in gefitinib-resistant lung cancer cell lines, SUZUKI Toshihiro ;NAGASAWA Ikuko;YAMAOKA Toshimitsu;OHMORI Tohru;NISHIO Kazuto;KOYAMA Kiyotaka;OGASAWARA Yuki, The 105th Annual Meeting of the American Association for Cancer Research, 07 Apr. 2014, San Diego
  • The characteristics of dual resistance to EGFR & MET inhibitors in pulmonary adenocarcinoma, PC-9 cells, YAMAOKA Toshimitsu;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;OKUDA Kentaro;TOYA Etsuko;OHBA Motoi;OHMORI Tohru;SASAKI Yasutsuna, 第72回日本癌学会学術総会, 03 Oct. 2013, 横浜
  • Clinical benefit of 2nd EGFR-TKI retreatment on overall survival in patients with advanced non-small cell lung cancer, NAKASHIMA Masanao;HIROSE Takashi;OHKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;ISHIDA Hiroo;OKUDA Kentaro;YAMAOKA Toshimitsu;OHMORI Tohru;OHNISHI Tsukasa, 第11回日本臨床腫瘍学会学術集会, 30 Aug. 2013, 仙台
  • The characteristics of an acquired dural resistance to EGFR & MET inhibitors in non-small cell lung cancer, harboring active mutation of EGFR, YAMAOKA Toshimitsu;ICHIHASHI Yoko;MURATA Yasunori;OKI Yasunari;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;OKUDA Kentaro;HIROSE Takashi;OHNISHI Tsukasa;OHMORI Tohru, AACR 104th Annual Meeting 2013, 10 Apr. 2013, Washington, DC
  • A novel c-MET inhibitor, tivantinib, shows an additive growth-inhibitory effect with erlotinib through enhanced degradation of c-MET protein via its recycling pathway, OHMORI Tohru;KANOME Tomoko;YAMAOKA Toshimitsu;HIROSE Takashi;KOIZUMI Fumiaki;NISHIO Kazuto;AKINAGA Shiro, 19th International Charles Heidelberger Symposium on Cancer Research, 14 Feb. 2013, Kagoshima
  • Carboplatin+Paclitaxel+Bevacizumabによる化学療法中にIII度房室ブロックをきたした肺腺癌症例, 白井　崇生;廣瀬　敬;大木　康成;村田　泰規;楠本　壮二郎;杉山　智英;石田　博雄;中嶌　賢尚;奥田　健太郎;大西　司;足立　満;山岡　利光;大森　亨, 第53回日本肺癌学会総会, 08 Nov. 2012, 岡山
  • 進展型小細胞肺癌の生存期間に対するアムルビシンの影響に関する検討., 石田　博雄;大木　康成;村田　泰規;石田　孔子;楠本　壮二郎;杉山　智英;白井　崇生;中嶌　賢尚;山岡　利光;奥田　健太郎;大西　司;大森　亨;廣瀬　敬, 第50回日本癌治療学会学術集会, 25 Oct. 2012, 横浜
  • Cancer vaccination trial novel multiple peptides in previously treated advanced non-small-cell lung cancer (NSCLC), 廣瀬　敬;野田　秀裕;奥田　健太郎;阿部　誠治;大戸　祐治;杉山　智英;石田　博雄;白井　崇生;中嶌　賢尚;山岡　利光;大森　亨;吉田　浩二;中村　祐輔, 第71回日本癌学会学術総会, 19 Sep. 2012, 札幌
  • HSP70 causes EGFR-TKIs resistance in a mutant EGFR expressed non-small cell lung cancer, OHMORI Tohru;YAMAOKA Toshimitsu;ICHIHASHI Yoko;HIROSE Takashi;SAIJO Nagahiro, 第10回日本臨床腫瘍学会学術集会, 27 Jul. 2012, 大阪
  • Cancer Vaccination trial with novel multiple peptides in previously treated advanced non-small cell lung cancer., HIROSE Takashi;NODA Hidehiro;OKUDA Kentaro;ABE Seiji;OTO Yuji;KUSUMOTO Sojiro;SUGIYAMA Tomohide;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;YAMAOKA Toshimitsu;OHMORI Tohru;YOSHIDA Koji;NAKAMURA Yusuke;ADACHI Mitsuru, 2012 Annual Meeting of the American Society of Clinical Oncology, 01 Jun. 2012, Chicago
  • HSP 70 may cause EGFR-TKIs-resistance due to inhibit drug binding to EGFR in the cells that expressed mutant EGFR., OHMORI Tohru;KADOFUKU Tsuyoki;ICHIHASHI Yoko;YAMAOKA Toshimitsu;HIROSE Takashi;ADACHI Mitsuru;SAIJO Nagahiro, AACR 103rd Annual Meeting 2012, 02 Apr. 2012, Chicago
  • Specific epidermal growth factor receptor autophosphorylation sites promote epithelial cell chemotaxis and restitution., YAMAOKA Toshimitsu;FREY Mark;POLK D Brent;OKI Yasunari;MURATA Yasunori;SUGIYAMA Tomohide;KUSUMOTO Sojiro;ISHIDA Hiroo;SHIRAI Takao;NAKASHIMA Masanao;OKUDA Kentaro;OHNISHI Tsukasa;HIROSE Takashi;OHMORI Tohru;ADACHI Mitsuru, AACR 103rd Annual Meeting 2012, 02 Apr. 2012, Chicago

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.